Anavex Life Sciences Corp. (AVXL) Soars on Parkinson's Drug Data

Anavex Life Sciences Corp. (AVXL) is bouncing back on drug data showing promise for Parkinson's disease

Sep 22, 2016 at 12:35 PM
facebook twitter linkedin

Just one day off an annual low, Anavex Life Sciences Corp. (NASDAQ:AVXL) is popping off today, after the biotech stock announced that its ANAVEX 2-73 drug has shown promise in restoring function in "a classic animal model of Parkinson's disease." The compound has already shown promise in both human subjects as well as in Phase 2a trials for Alzheimer's disease. In the option pits, calls are hot, as AVXL attempts to topple a trendline not conquered since late July.

AVXL is up 27.6% at $3.33 so far today, muscling above the $3 level that acted as support in August. The stock is also on track to close above its 30-day moving average for the first time since its late-July bear gap. Longer term, though, the stock has lost nearly 78% of its value since touching a four-year peak in November, with subsequent rebound attempts halted in the $8 region.

In the option pits, peak open interest sits at the out-of-the-money October 5 call, with just under 2,900 contracts open. This option is also the most popular today, and while volume is light on an absolute basis, AVXL calls are crossing the tape at 16 times the average intraday rate. Some of the call buying at this strike could be hedging action, however. AVXL's short interest -- previously at a record-high -- is down by 21.9% over the last two reporting periods, but shorted shares still account for 10.8% of AVXL's float, which would take 8.3 days of trading to cover, at AVXL's average daily volume. 

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Best stocks for October and worst stocks for October


Special Offers from Schaeffer's Trading Partners